News Biogen courts controversy with $750k-a-year rare disease dru... Biogen's SMA treatment approved - but price is $125,000 per dose
News Gilead ordered to pay Merck & Co $2.54 bn by US court Ruling relates to infringement of patents held by Merck subsidiary
News Intercept's Ocaliva approved in EU for liver disease Potential liver blockbuster gets EU licence.
News NHS England confirms HIV prevention funding - but only via c... Large trial of HIV PrEP could lead to national programme
News AbbVie taking on Gilead with eight-week hep C course Latest combination drug resulted in 97.5% cure rates across all major disease strains
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
